1Fujii M, Kochi M, Mochizuki F. Significance of neoadjuvant emotherapy for gastric cancer [J]. Gall To Kagaku Ryoho,2000,27 ( 11 ) : 2028-2032. 被引量：1
2Elliot NE, Marcus SG, Potmcsil M, et al. Neoadjuvant chemotherapy with CPT211and cisplatin downstages locally advanced gastric cancer [J ]. Gastrointest Surg, 2002,6 ( 2 ) : 212 -223. 被引量：1
3Macdonald JS, Smalley SR, Benedetti J,et al. Chemora-diotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junc-tion[ J J. N Engl J Med,2001,345 (10) :725-730. 被引量：1
4Wilke H, Preusser P, Fink U ,et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase Ⅱ study with etoposide, doxorubicin, and cisplatin [ J ]. J Clin Oncol, 1989,7(9) :1318. 被引量：1
5Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy[ J]. Ann Surg Oncol, 2002,9 (4) : 394-400. 被引量：1
6Thirion PG, Michiels S, Le Maitre A, et al. Ilndividual patient data- based meta-analysis assessing pre-operafive chemotherapy in resectable oesophageal carcinoma[J]. Journal of Clinical Onedogy,2007, 25(18S) :4512. 被引量：1
7Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine [ J ]. N Engl J Med,2007,357 ( 18 ) : 1810-1820. 被引量：1
4Goldstein D, Mitchell P, Michal M, et al. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer Patients[J]. Br J Cancer,2005, 92(5) :832-837. 被引量：1
5Hsuen Lim E, Seng Cheong Lim R, Seng Wu T, et al. Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma:an asian experience[J]. Pann Pharmacother,2003,37(12) :1909-1912. 被引量：1
6Kemeny N, Garay C A, Gurtler J, et al. Randomized multicenter phase Ⅱ trial of bolus plus in FU sional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer [J]. J Clin Oncol,2005,23(1) :248-252. 被引量：1
7Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics,2002[J]. CA Cancer J Clin, 2005, 55(2) :74-108. 被引量：1
8Rixe O, Ortuzar W,Alvarez M, et al. Oxaliplatin,tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant celllines and in the cell lines of the National Cancer Institute ' s Anticancer Drug Screen panel[J]. Biochem Pharmacol, 1996,52 (12): 1855 -1865. 被引量：1
9Kuebler J P,de Gramont A. Recent Experience With Oxaliplatin or lrinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer[J]. Semin Oncol,2004,30(4 Suppl 15) :40-47. 被引量：1
10Simpson D, Dunn C, Curran M. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer [J]. Drugs, 2003,63(19) :2127-2156. 被引量：1
